Compare BioNano Genomics Inc (BNGO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Under Armour Inc Class A — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Under Armour Inc Class A trades at $6.81 (market cap $2.79B). The key difference: Under Armour Inc Class A is far larger — about 211.4× BioNano Genomics Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | UA | |
|---|---|---|
Market Cap | $13.20M | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $7.88 |
52-Week Low | $1.09 | $3.96 |
Enterprise Value | $15.81M | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Under Armour (UA) trades at $6.61 with a neutral daily performance. The stock shows bullish technical signals from moving averages but faces fundamental challenges with negative net income margins (-9.98%) and declining revenue projections for 2026. Recent earnings showed mixed results with a Q1 2026 miss, while analyst sentiment remains divided with 40.3% buy ratings. The company's cash flow trends show significant outflows, with net cash flow negative $361.87 million in 2025.
The outlook remains cautious due to ongoing revenue declines and profitability challenges, though technical strength and institutional buying by investors like Prem Watsa provide some support. Key risks include sustained negative earnings, competitive pressures, and execution of the company's turnaround strategy. The stock presents a speculative opportunity for investors believing in management's premium product focus and inventory discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
